Clinical Trial Update: Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ [Phase 2]

View source ↗

Summary

A completed Phase 2 trial assessed the safety of two applications of PEP005 topical gel for treating cutaneous squamous cell carcinoma in situ (Bowen disease).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma in Situ
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• PEP005 Topical Gel (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Carcinoma, Squamous Cell | Phase 2 | Status: COMPLETED